2月4日恰逢立春节气。在这象征希望与新生的日子里，北京恒昌公益基金会(简称"恒昌公益")第四届"暖 冬公益季"北京站于首都医科大学附属首都儿童医学中心(简称"首都儿童医学中心")温情启幕。 情暖童心，"益"马当先。恒昌公益秘书长云龙、流动党员党支部书记宋贵龙携志愿者走进病房，将柔软 暖心的童帽、饱含寓意的"希望种子礼盒"送到正在接受治疗的患儿手中。作为第四届"暖冬公益季"继厦 门、广州之后的收官之站，恒昌公益以切实行动回应儿童健康关切，响应"健康中国"战略，守护祖国未 来蓬勃生长，为凛冽寒冬注入融融暖意。 立春送暖 传递希望 健康，是文明最朴素的底色，更是发展最坚实的根基。《"健康中国2030"规划纲要》中明确提出，实施 健康儿童计划，加强儿童早期发展，加强儿科建设，加大儿童重点疾病防治力度，扩大新生儿疾病筛 查，继续开展重点地区儿童营养改善等项目。在此国家战略指引下，一套覆盖全生命周期、惠及全体人 民的健康服务体系正在加速构建，而公益力量正成为推动医疗健康事业高质量发展的重要引擎。 立春当日，首都儿童医学中心医务社工于金辉、郭一薄陪同恒昌公益秘书长云龙、党支部书记宋贵龙及 志愿者一行走进普外科、骨科等病房， ...

2月1日，医疗人工智能协同创新论坛暨医疗人工智能联盟（筹）2026年第一次学术会议在上海练秋湖华为研发中心举办。华为云在会上发布"行业AI梦工 厂"首个专区——智慧医疗专区，明确在医疗AI领域的布局，目标以技术创新破解医疗资源均衡难题，推动医疗AI普惠。 第二项重磅举措，是华为云"行业AI梦工厂"首个专区——智慧医疗专区的正式推出。据周跃峰介绍，技术只有解决行业问题，才能创造真正价值。该专区深 度融合了瑞金医院等头部医疗机构的先进临床经验，以及华为在ICT、云、AI等领域的技术沉淀与实践成果。它将为基层医院及医生、合作伙伴、开发者提 供一套覆盖场景、模型、平台到社区的端到端支撑体系，让AI真正普惠每一家医院、每一位医生、每一名患者。 第三项举措是关于生态建设。周跃峰强调，医疗AI的普惠从来不是一家企业能单独完成的使命，生态共筑才是关键，要聚产业之力，共建共享，才能让医 疗AI创新更简单。华为呼吁更多医疗机构、科技企业和开发者加入进来，共同建设智慧医疗专区。通过共建共享领先的行业模型、高质量数据集、场景化 应用与AI工具链，降低医疗AI创新的门槛，加速医疗AI的规模化落地与普惠应用。 从夯实数字底座到打造智慧医 ...

齐鲁晚报.齐鲁壹点通讯员曹婷婷 会上，甘肃医学院相关负责人介绍了甘肃医学院的基本情况、办学背景以及发展需求。他表示，甘肃医学院扎根陇原六十余载，始终以"培育医药人才、 服务地方健康"为己任。此次与鲁南制药集团的合作，是全力推动教育科技人才一体化发展、加快构建医学教育创新与医药产业协同发展新格局的重要举 措。希望双方以此次合作为契机，依托鲁南制药集团先进的科研设施与产业化经验，共同开展中药现代化研究、道地药材标准化体系建设，积极探索"党 建共建+产学研融合"的新模式，校企协同发展，共同助力甘肃中医药产业升级与基层健康服务能力提升。 2月1日，鲁南制药集团与甘肃医学院战略合作协议签约仪式举行。 鲁南制药集团相关负责人结合企业实践，以《"中正平和"在启达力中的呈现》为主题进行分享。他指出，"中正平和"不仅是中医药文化的核心理念，也是 鲁南制药集团在产品研发与企业经营中一贯秉持的价值追求。以"启达力荆防颗粒"为例，该产品秉承"平衡组方、温和起效、持久稳定"三大特点，旨在通 过科学诠释传统智慧，实现现代医药与传统哲学的深度融合。未来，鲁南制药集团坚持"疗效优先"，致力于研发更安全、更有效的医药产品，为患者提供 更可靠的 ...

【人物】8772乐队 【事件】8772乐队成立于2015年，队名源自"病痛挑战"拼音首字母缩写"BTTZ"的数字变形。乐队成员 都是罕见病患者或残障人士，主音吉他手因患脊髓灰质炎失去行走能力、贝斯手患有血友病、鼓手患有 重症肌无力。乐队以音乐为媒介，为罕见病群体发声，传递"病痛只是一种状态，人人生而平等、人人 都有尊严"的信念。不久前，这支乐队在北京举办了成立10周年音乐会，近500名观众到场支持。 【点评】 一支乐队，见证一群罕见病患者向阳而生。 《人民日报》（2026年02月03日05版） 他们的音乐何以动人？或许源于充满韧性的"反差感"。 责编：秦雅楠、王瑞景 从《呐罕》中"我吼一声就划破天"的呐喊，到《小梦想》中"有梦说出来我们为你鼓掌"的喝彩，再到为 脊髓性肌萎缩症病友包珍妮创作的《予生》，10年间，8772乐队发表了13首歌，参与了上百场演出。 旋律的流淌、节奏的跳跃、和弦的交织，音乐，往往承载着自由、浪漫等美好情愫，与人们对病痛的想 象截然相反。存在主义哲学家曾说过"存在先于本质"，而8772乐队，正是在用音乐告诉世界，病痛只是 生命形态的一种，而非人生的本质定义；即使深陷病痛的泥淖，也要用热爱 ...

Group 1 - The company expects to achieve an annual revenue of 351 million yuan for 2025, remaining stable compared to the previous year [1] - The net profit attributable to shareholders is projected to be -409 million yuan, with a net profit of -148 million yuan after excluding non-recurring gains and losses, also stable year-on-year [1] - The decline in performance is primarily due to the underperformance of the company's investment in Shenzhou Medical Technology Co., leading to an expected loss of approximately 260 million yuan from fair value changes of financial assets [1] Group 2 - The company aims to align with the "Healthy China" initiative and the "Three Medical Coordination" reform, focusing on the digitalization and informatization of the healthcare industry [2] - The core strategy revolves around the aggregation, circulation, and application of health big data, targeting areas such as comprehensive management of medical insurance funds and healthcare service innovation [2] - The company is actively exploring investment collaborations to support the "Healthy China" strategy with technical support and professional services [2]

Core Viewpoint - The article highlights the successful resolution of a unique case where a foreign resident in Jining, Malaysia-born Zhang Zhenhan, was able to use the medical insurance electronic voucher for the first time in Shandong Province, showcasing the extension of medical insurance services to a broader demographic [2][6]. Group 1: Case Background - Zhang Zhenhan, a Malaysian national living in Jining for over ten years, faced difficulties using his medical insurance electronic voucher at a pharmacy due to mismatched identity information in the system [3][4]. - Despite having paid into the medical insurance system for years, Zhang encountered issues when attempting to use the electronic voucher for medication, which he found convenient compared to traditional methods [3][6]. Group 2: Problem Resolution - The staff at the medical insurance window, including Li Shuai, coordinated with various stakeholders, including the National Medical Insurance Center and a third-party technical company, to address the issue [4][5]. - A WeChat group was created to facilitate communication among all parties involved, allowing for real-time updates and problem-solving [5][6]. - After identifying that the issue stemmed from the standardization of Zhang's name in the system, adjustments were made, but further complications arose due to the pharmacy's electronic prescription system not recognizing foreign identification types [6][7]. Group 3: Successful Outcome - Ultimately, the issues were resolved by mid-December 2025, allowing Zhang to successfully use the electronic voucher for a medication purchase, marking a significant milestone as the first case of a foreigner using the medical insurance electronic voucher in Shandong [6][8]. - Zhang expressed gratitude for the attentive service provided by the medical insurance staff, highlighting the importance of such services for foreign residents [6][8]. Group 4: Broader Implications - The case illustrates the ongoing efforts to create a more inclusive medical insurance network in China, extending services to foreign residents and enhancing their sense of belonging in the community [7][8]. - Zhang's commitment to promoting a more civilized and convenient environment in Jining reflects the broader goals of the local government to improve public services and integrate foreign residents into the community [8].

Group 1 - The company, Guo Xin Health, is forecasting a loss for the fiscal year 2025, with an expected operating revenue of approximately RMB 351 million, which is roughly in line with the previous year [1][3] - The net profit attributable to shareholders is projected to be around RMB -4.09 billion, primarily due to an expected impairment loss of RMB 260 million on trading financial assets [3][11] - The decline in the value of trading financial assets is linked to the underperformance of Shenzhou Medical Technology Co., Ltd., in which the company holds a 7.66% stake [3][8] Group 2 - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the company and the auditors concerning the forecast [2] - The fair value of the trading financial assets held by the company was approximately RMB 407.81 million at the end of 2024, and it is expected to decrease by RMB 260 million by the end of 2025 [10][11] - The company emphasizes that the financial data presented is preliminary and has not been audited, urging investors to exercise caution [9][11]

【大河财立方 记者 席韶阳 通讯员 唐爱红】新华保险在医康养生态领域再添重磅战略合作对象。近日，新华保险与New Frontier Group Limited（以下简称新 风天域集团）在北京举行战略合作签约仪式。双方将合作升级"保险+医疗健康"融合模式，为客户提供覆盖全生命周期的医疗健康解决方案。 新风天域集团表示，本次与新华保险达成战略合作，双方将共同努力开创"保险+医疗健康"融合新篇章，未来将依托其多元化的业务矩阵，为"保险+医疗"融 合模式提供支持。未来合作中，双方将充分发挥各自优势，共同探索并推动"服务给付型健康保险"产品的创新与发展，为新华保险的客户提供更安全、专业 和便捷的医疗健康服务。 新华保险长期锚定"中国一流的以保险业务为核心的金融服务集团"发展愿景，深化"保险+服务+投资"三端协同。新华保险相关负责人表示，未来，将以此次 战略合作为新起点，继续携手新风天域集团等生态伙伴，持续深化"保险+医疗健康"模式，扎实推进资源整合、提升服务协同能力，持续拓展医疗服务网 络，优化健康管理服务闭环，扎实构建"卓越医疗"服务体系，为"健康中国"建设注入新动能。 据悉，为积极响应"健康中国"战略，推动保险保障 ...

Core Viewpoint - Guoxin Health has released a performance forecast, expecting a total operating revenue of 350.77 million yuan for the year 2025, with a focus on health data and digital transformation in the healthcare sector [1] Group 1: Performance Forecast - The company anticipates an operating revenue of approximately 350.77 million yuan for 2025 [1] - The net profit attributable to shareholders is expected to be around -409 million yuan [1] Group 2: Financial Performance - For the first three quarters of 2025, the company's main revenue was 170 million yuan, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders for the same period was -138 million yuan, a year-on-year decline of 347.32% [2] - The company's gross profit margin was reported at -5.15% [2] Group 3: Quarterly Performance - In Q3 2025, the company's single-quarter main revenue was 74.87 million yuan, an increase of 19.26% year-on-year [2] - The net profit attributable to shareholders for Q3 was -39.34 million yuan, a year-on-year decrease of 193.59% [2] - The company reported a debt ratio of 37.02% and investment income of 16.57 million yuan [2] Group 4: Reasons for Performance Changes - The increase in losses is primarily due to expected impairment of trading financial assets, particularly related to Shenzhou Medical Technology Co., Ltd., which has seen a decline in operating performance [1]

Core Viewpoint - Guoxin Health expects a total operating revenue of 351 million yuan for the year 2025, maintaining stability compared to the previous year [1] Group 1: Financial Performance - For the first three quarters of 2025, the company's main revenue was 170 million yuan, a year-on-year decrease of 14.87% [2] - The net profit attributable to shareholders was -138 million yuan, a year-on-year decline of 347.32% [2] - The net profit after deducting non-recurring gains and losses was -138 million yuan, a year-on-year decrease of 27.09% [2] - In Q3 2025, the company's single-quarter main revenue was 74.87 million yuan, a year-on-year increase of 19.26% [2] - The single-quarter net profit attributable to shareholders was -39.34 million yuan, a year-on-year decline of 193.59% [2] - The single-quarter net profit after deducting non-recurring gains and losses was -39.37 million yuan, a year-on-year decrease of 29.67% [2] - The company's debt ratio stood at 37.02% [2] - Investment income was 16.57 million yuan, while financial expenses amounted to 6.53 million yuan [2] - The gross profit margin was -5.15% [2] Group 2: Strategic Focus - The company is aligning its operations with the "Healthy China" initiative and the "Three Medical Collaborations" reform, focusing on health data integration and digital transformation [1] - The strategic focus includes comprehensive management services for medical insurance funds, medical quality and safety services, and health service innovation [1] - The company aims to leverage data value and actively pursue investment collaborations to support the national strategy for "Healthy China" [1] Group 3: Asset Impairment - The increase in losses is primarily due to expected impairment of trading financial assets, specifically a 99.01% partnership interest in Shenzhou Borui (Shenzhen) Investment Enterprise [1] - The decline in operating performance of Shenzhou Medical Technology Co., Ltd., in which Shenzhou Borui holds a 7.66% stake, is anticipated to result in a fair value loss of approximately 260 million yuan on the company's trading financial assets [1]